In SCLC, early investigational efforts are exploring CAR-T constructs directed against targets such as CDH17, GD2, and PTK7, which are selected based on tumor-enriched expression patterns similar to those leveraged by ADCs and T-cell engagers [76,77,78]. This evidence concerns the gene CDH17 and neoplasm.